Advances and Challenges on Management of Gastrointestinal Stromal Tumors
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Advances and Challenges on Management of Gastrointestinal Stromal Tumors
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-05-07
DOI
10.3389/fonc.2018.00135
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas
- (2018) Maud Toulmonde et al. JAMA Oncology
- Classification of gastrointestinal stromal tumor syndromes
- (2017) Priya Gopie et al. ENDOCRINE-RELATED CANCER
- Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic
- (2017) Christopher B. Weldon et al. JOURNAL OF CLINICAL ONCOLOGY
- Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels
- (2017) Paolo G. Casali et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Gastrointestinal Stromal Tumors
- (2017) Emily Z. Keung et al. SURGICAL CLINICS OF NORTH AMERICA
- Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib
- (2017) Heikki Joensuu et al. JAMA Oncology
- NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
- (2017) George D. Demetri et al. Journal of the National Comprehensive Cancer Network
- Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial
- (2016) Peter Reichardt et al. BMC CANCER
- Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies
- (2016) Kjetil Søreide et al. Cancer Epidemiology
- Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial
- (2016) Heikki Joensuu et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular and morphological correlation in gastrointestinal stromal tumours (GISTs): an update and primer
- (2016) Runjan Chetty et al. JOURNAL OF CLINICAL PATHOLOGY
- Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial
- (2016) Olivier Mir et al. LANCET ONCOLOGY
- Management of Gastrointestinal Stromal Tumors
- (2016) Margaret von Mehren SURGICAL CLINICS OF NORTH AMERICA
- Molecular Subtypes ofKIT/PDGFRAWild-Type Gastrointestinal Stromal Tumors
- (2016) Sosipatros A. Boikos et al. JAMA Oncology
- Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1
- (2015) Yujiro Hayashi et al. GASTROENTEROLOGY
- Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas
- (2015) Paolo G. Casali et al. JOURNAL OF CLINICAL ONCOLOGY
- Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial
- (2015) Jean-Yves Blay et al. LANCET ONCOLOGY
- Combined Inhibition of MAP Kinase and KIT Signaling Synergistically Destabilizes ETV1 and Suppresses GIST Tumor Growth
- (2015) L. Ran et al. Cancer Discovery
- BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance
- (2015) Gerald S. Falchook et al. Oncotarget
- Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
- (2014) A. Adenis et al. ANNALS OF ONCOLOGY
- Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study
- (2014) Sasja F Mulder et al. BMC CANCER
- Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial
- (2014) Christopher L. Corless et al. JOURNAL OF CLINICAL ONCOLOGY
- Recent advances in the treatment of gastrointestinal stromal tumors
- (2014) César Serrano et al. Therapeutic Advances in Medical Oncology
- A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib
- (2013) K. N. Ganjoo et al. ANNALS OF ONCOLOGY
- Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor
- (2013) Ronald P. DeMatteo et al. ANNALS OF SURGERY
- Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial
- (2013) Yoon-Koo Kang et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial
- (2012) A. Patrikidou et al. ANNALS OF ONCOLOGY
- Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib
- (2012) P. Reichardt et al. ANNALS OF ONCOLOGY
- Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib‡
- (2012) S. George et al. ANNALS OF ONCOLOGY
- Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors
- (2012) M. C. Heinrich et al. CLINICAL CANCER RESEARCH
- Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group
- (2012) S. H. Park et al. INVESTIGATIONAL NEW DRUGS
- One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor
- (2012) Heikki Joensuu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial
- (2012) Suzanne George et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132
- (2011) Dian Wang et al. ANNALS OF SURGICAL ONCOLOGY
- Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
- (2011) Hagop M Kantarjian et al. LANCET ONCOLOGY
- Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts
- (2011) Heikki Joensuu et al. LANCET ONCOLOGY
- Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)
- (2010) Axel Le Cesne et al. EUROPEAN JOURNAL OF CANCER
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients
- (2010) JOURNAL OF CLINICAL ONCOLOGY
- Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial
- (2010) Axel Le Cesne et al. LANCET ONCOLOGY
- Monoclonal Antibody DOG1.1 Shows Higher Sensitivity Than KIT in the Diagnosis of Gastrointestinal Stromal Tumors, Including Unusual Subtypes
- (2009) Bernadette Liegl et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers
- (2009) J.C. Soria et al. EUROPEAN JOURNAL OF CANCER
- Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
- (2009) S. George et al. EUROPEAN JOURNAL OF CANCER
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
- (2009) Ronald P DeMatteo et al. LANCET
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
- (2008) Michael C. Heinrich et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- Early Prediction of Response to Sunitinib After Imatinib Failure by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Gastrointestinal Stromal Tumor
- (2008) John O. Prior et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665
- (2008) Burton L. Eisenberg et al. JOURNAL OF SURGICAL ONCOLOGY
- Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)
- (2007) Ronald P. DeMatteo et al. CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More